Not every breast lump is cancer, but every new or changing lump deserves a clear assessment. Kebeza helps organise clinical review, the right imaging or sampling pathway and understandable next steps.
A lump, nipple change, skin change, persistent focal pain or an abnormal breast image can have several causes. The safe next step is a clinical assessment that decides whether imaging, needle sampling, biopsy or another review is appropriate.
Kebeza's role is to help connect those steps and make the result understandable. WhatsApp guidance cannot diagnose or rule out breast cancer.
Kebeza begins with what you have noticed, how it has changed and any prior breast imaging, sampling or family history relevant to the clinical review.
A qualified clinician assesses the breast concern and decides which evidence is needed next. The pathway depends on the individual finding.
Depending on the review, the next step may include breast imaging, FNAC, core biopsy or another specialist assessment. Not every lump needs every test.
Kebeza helps explain the report, clarify what remains uncertain and organise follow-up, second opinion or referral where appropriate.
If you have only noticed a lump, begin with assessment. If imaging has already recommended sampling, ask about the biopsy pathway. If you already hold a pathology report, ask for result explanation or second-opinion guidance.
Kebeza's pathway is aligned with public guidance that most breast lumps are not cancer, but an abnormal lump or breast change should still receive clinical evaluation and appropriate diagnosis.
No. Many breast lumps are not cancer, but a new or changing lump should be assessed so the appropriate examination or test can be selected.
No. WhatsApp can help organise the next step, but diagnosis requires appropriate clinical assessment and, when indicated, imaging or laboratory testing.
Bring or send the available report through an agreed secure route. Kebeza can help explain it and organise appropriate follow-up or a second opinion.